Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life and Health Insurance Industry Analysis

UpdatedJul 30, 2026
DataAggregated Company Financials
Companies21
  • 7D2.6%
  • 3M15.9%
  • 1Y27.5%
  • YTDn/a

Over the last 7 days, the Life and Health Insurance industry has risen 2.6%, driven by gains in Aflac and MetLife of 4.1% and 4.0%, respectively. This takes the industry's 12 month performance to a gain of 27%. Looking forward, earnings are forecast to grow by 9.5% annually.

Industry Valuation and Performance

Has the U.S. Life and Health Insurance Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 31 Jul 2026US$283.4bUS$265.1bUS$18.7b14.1x15.2x1.1x
Sun, 28 Jun 2026US$261.3bUS$264.8bUS$18.7b14.9x14x1x
Tue, 26 May 2026US$251.7bUS$264.8bUS$18.7b13.5x13.5x1x
Thu, 23 Apr 2026US$245.7bUS$260.4bUS$16.6b15.6x14.8x0.9x
Sat, 21 Mar 2026US$223.7bUS$260.7bUS$16.7b14x13.4x0.9x
Mon, 16 Feb 2026US$240.2bUS$261.2bUS$17.4b15.3x13.8x0.9x
Wed, 14 Jan 2026US$246.7bUS$255.6bUS$19.7b12.9x12.5x1x
Fri, 12 Dec 2025US$249.3bUS$255.6bUS$19.7b12.9x12.6x1x
Sun, 09 Nov 2025US$245.0bUS$255.7bUS$19.2b13.4x12.8x1x
Tue, 07 Oct 2025US$257.1bUS$254.5bUS$15.7b13.3x16.4x1x
Thu, 04 Sep 2025US$248.9bUS$254.5bUS$15.7b14x15.9x1x
Sat, 02 Aug 2025US$240.1bUS$256.2bUS$17.3b12x13.9x0.9x
Mon, 30 Jun 2025US$230.8bUS$243.3bUS$17.6b12.5x13.1x0.9x
Wed, 28 May 2025US$222.6bUS$243.3bUS$17.6b12.4x12.7x0.9x
Fri, 25 Apr 2025US$224.0bUS$250.3bUS$22.4b10.8x10x0.9x
Sun, 23 Mar 2025US$238.5bUS$250.3bUS$22.4b11.3x10.7x1x
Tue, 18 Feb 2025US$232.8bUS$249.4bUS$21.6b12.2x10.8x0.9x
Thu, 16 Jan 2025US$232.6bUS$242.9bUS$14.3b14.1x16.3x1x
Sat, 14 Dec 2024US$233.9bUS$242.9bUS$14.3b14x16.4x1x
Mon, 11 Nov 2024US$237.0bUS$242.9bUS$14.2b14.5x16.7x1x
Wed, 09 Oct 2024US$238.6bUS$229.8bUS$16.6b13.4x14.4x1x
Fri, 06 Sep 2024US$236.9bUS$229.8bUS$16.6b12.9x14.3x1x
Sun, 04 Aug 2024US$217.0bUS$228.0bUS$16.4b10.2x13.2x1x
Tue, 02 Jul 2024US$216.9bUS$225.4bUS$14.8b10.5x14.6x1x
Thu, 30 May 2024US$213.3bUS$225.4bUS$14.8b10.3x14.4x0.9x
Sat, 27 Apr 2024US$211.2bUS$218.2bUS$11.0b14.4x19.3x1x
Mon, 25 Mar 2024US$220.3bUS$216.9bUS$10.3b15.1x21.5x1x
Wed, 21 Feb 2024US$212.8bUS$209.6bUS$10.3b13.6x20.6x1x
Fri, 19 Jan 2024US$256.6bUS$213.6bUS$2.7b13.3x94.8x1.2x
Sun, 17 Dec 2023US$253.8bUS$216.4bUS$1.6b13.4x155.8x1.2x
Tue, 14 Nov 2023US$239.4bUS$216.4bUS$1.6b10.9x147.1x1.1x
Thu, 12 Oct 2023US$244.2bUS$238.9bUS$1.0b12.8x238.9x1x
Sat, 09 Sep 2023US$240.5bUS$238.9bUS$1.0b12.9x235.2x1x
Mon, 07 Aug 2023US$247.3bUS$239.9bUS$3.5b13.7x69.8x1x
Price to Earnings Ratio

69.8x


Total Market Cap: US$247.3bTotal Earnings: US$3.5bTotal Revenue: US$239.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life and Health Insurance Industry Price to Earnings3Y Average 41.2x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life and Health Insurance industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 15.2x which is lower than its 3-year average PE of 41.2x.
  • The industry is trading close to its 3-year average PS ratio of 0.99x.
Past Earnings Growth
  • The earnings for companies in the Life and Health Insurance industry have grown 74% per year over the last three years.
  • Revenues for these companies have grown 3.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does U.S. Life and Health Insurance compare with similar industries?

US Market-2.63%
Financials0.96%
Insurance5.79%
Life and Health Insurance2.56%
Insurance Brokers10.29%
Property and Casualty Insurance5.35%
Reinsurance3.50%
General Insurance1.63%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MET MetLifeUS$97.074.9%
+US$2.9b		27.8%PE18.2x
PRU Prudential FinancialUS$122.774.2%
+US$1.7b		18.5%PE12.4x
AFL AflacUS$127.362.4%
+US$1.5b		28.2%PE14x
PFG Principal Financial GroupUS$113.956.2%
+US$1.2b		46.4%PE15.7x
LNC Lincoln NationalUS$46.0212.7%
+US$992.4m		20.8%PE5.4x

Latest News

PFG
US$113.95
Principal Financial Group
7D
6.2%
1Y
46.4%
UNM
US$86.77
Unum Group
7D
0.4%
1Y
20.8%
MET
US$97.07
MetLife
7D
4.9%
1Y
27.8%
PRU
US$122.77
Prudential Financial
7D
4.2%
1Y
18.5%
GL
US$182.98
Globe Life
7D
7.0%
1Y
30.3%
Narrative Update • Jul 28

GL: Earnings Miss Share Repurchases And Guidance Will Shape Future Returns

Analysts have raised their price target for Globe Life from $172.10 to approximately $190.09, reflecting updated models that incorporate a slightly higher discount rate, modestly different expectations for revenue growth and profit margins, and a higher assumed future P/E multiple. What’s in the News for Globe Life Globe Life shares fell 7.2% after reporting Q2 2026 net operating income of $3.61 per diluted share, which missed the $3.79 consensus estimate by 4.7%.
AFL
US$127.36
Aflac
7D
2.4%
1Y
28.2%
Narrative Update • Jul 25

AFL: Future Returns Will Reflect Supportive Macro Conditions And Execution Risk Balancing

Aflac's fair value estimate has been raised from about $114.86 to $117.71 as analysts incorporate higher sector price targets, modestly higher assumed future P/E multiples, and a slightly stronger profit margin outlook supported by a more supportive macro backdrop and reduced private credit concerns across life insurers. Analyst Commentary Recent Street research on Aflac reflects a wide range of views on valuation and execution, even as most firms have adjusted their price targets upward in the run up to Q2 earnings.
OSCR
US$31.23
Oscar Health
7D
8.0%
1Y
122.3%
Narrative Update • Jul 25

OSCR: ACA Exchange Risk Adjustment Tailwind Will Not Offset Margin Concerns

Analysts have lifted the implied fair value estimate for Oscar Health from $22.60 to $24.20, citing more supportive views on the 2025 healthcare exchange risk adjustment true up and the company’s focused exposure to the individual ACA market, even as margin expectations remain measured and the future P/E assumption edges up toward 11x. Analyst Commentary Recent research on Oscar Health centers on how the individual Affordable Care Act market, risk adjustment outcomes, and margin trajectory could feed into valuation over the next few years.
PRI
US$323.32
Primerica
7D
4.9%
1Y
21.7%
Narrative Update • Jul 22

PRI: Future Returns Will Be Shaped By Buybacks And Stable Profitability

Analysts have nudged their average price target for Primerica higher, lifting fair value from $298.50 to about $308.67 as they update their models to reflect modestly adjusted assumptions for revenue growth, profit margin and future P/E expectations. What's in the News for Primerica Primerica was dropped from the Russell 1000 Dynamic Index, according to a key index constituent update.
LNC
US$46.02
Lincoln National
7D
12.7%
1Y
20.8%
Narrative Update • Jul 22

LNC: Capital Releases From Reinsurance And Buybacks Will Drive Future Repricing

The analyst fair value estimate for Lincoln National has moved to $57.00 from $54.11, reflecting Street research that points to improved sector valuations, a more supportive macro backdrop, and company specific factors such as stronger excess cash and potential capital returns. Analyst Commentary Recent research on Lincoln National highlights a series of upward price target revisions and rating changes that collectively point to improving sentiment around the stock.
CIA
US$4.86
Citizens
7D
-1.2%
1Y
27.2%
Analysis Article • May 11

Citizens, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Citizens, Inc. ( NYSE:CIA ) missed earnings with its latest first-quarter results, disappointing overly-optimistic...